Summary As part of an 'enzyme-directed' approach to bioreductive drug development, we have measured the activity of NADH:cytochrome b5 reductase (B5R) in human cancer cell lines in order to assess the role of this enzyme in activating bioreductive drugs, and thus in influencing the cytotoxicity of these compounds. At present, there is no validated assay reported in the literature for measuring the activity of B5R in tumour cells, and current measurements have assumed that the enzyme activity can be measured either as the NADHdependent reduction of cytochrome c or as the non-dicoumarol-inhibitable activity in the DT-diaphorase assay. Using p-hydroxymercuribenzoate (pHMB) as an inhibitor of B5R, we have quantified the contribution of B5R to the NADH-dependent reduction of cytochrome c and to the overall reduction of cytochrome c in the DTdiaphorase assay. In the former we found that residual uninhibited activity remained in the presence of pHMB, in some cases accounting for up to 60% of the total reduction of cytochrome c. Thus, simply measuring the NADH-dependent reduction of cytochrome c consistently overestimated B5R activity. We also found that the non-dicoumarol-inhibitable activity in the DT-diaphorase assay underestimated B5R activity, especially in cell lines with high DT-diaphorase activity. Therefore, we have developed a spectrophotometric assay for measuring B5R activity as the pHMB-inhibitable NADH-dependent reduction of cytochrome c. This has been used to measure the B5R activity of a panel of 22 human tumour cell lines, in which we found 7-fold and 3-fold variations in activity expressed per cell or per mg protein respectively.
Cytochrome b5 reductase (NADH:cytochrome b5 reductase; EC 1.6.2.2) is FAD-containing flavoprotein. The enzyme is usually bound to the endoplasmic reticulum, but has also been found bound to outer mitochondrial membranes in the liver (Sottocasa et al., 1967) and plasma membranes in erythrocytes (Choury et al., 1981) . In addition, an immunologically related soluble form of the enzyme has been purified from erythrocyte cytosol (Passon et al., 1972; Leroux et al., 1977) and from rabit liver cytosol (Lostanlen et al., 1987) . Cytochrome b5 reductase transfers reducing equivalents from NADH to cytochrome b5 in the endoplasmic reticulum, which, in turn, donates electrons to a variety of electron acceptors, which include fatty acid desaturases, elongase, cytochrome P450, methaemoglobin and metmyoglobin (Ghesquier et al., 1985; Guiray and Arinc, 1991) .
Cytochrome b5 reductase is potentially an important enzyme required for the reductive activation of bioreductive drugs that can be used in the treatment of solid tumours. These drugs are targeted specifically at the radiationinsensitive population of cells residing in hypoxic regions of tumours, where they are activated by cellular reductases generally only under conditions of low oxygen tension. In vitro studies have indicated that purified cytochrome b5 reductase is able to activate mitomycin C (Hodnick and Sartorelli, 1993) , although its role in the whole cell is unclear.
We have recently shown that microsomal cytochrome b5 reductase is intimately involved in the activation of the fused pyrazaine mono-N-oxide bioreductive drug, RB90740 (Barham and Stratford, 1996) . We, therefore, wanted to extend this study by characterising the expression and activity of this enzyme in a large panel of human cancer cell lines. This would enable the suitability of RB90740 as a candidate for the 'enzyme-directed' approach to bioreductive drug development (Workman and Walton, 1989; Workman and Stratford, 1993) to be assessed. This requires knowledge not only of the enzymology of drug activation, but also of the level of activity of appropriate enzymes in different tumour types. Thus, in theory a bioreductive drug can be targeted at a particular tumour type according to its enzyme profile.
Cytochrome b5 reductase has not been widely studied as a bioreductive enzyme, and there is no simple assay for measuring its activity in tumour cells. The activity of the purified enzyme is usually measured using cytochrome b5 as substrate (Tamura et al., 1988; Guiray and Arinc, 1991) . However, cytochrome b5 is not available commercially, and, therefore, must be purified from liver. The activities of other reductase enzymes such as NADPH: cytochrome P450 reductase or DT-diaphorase, both of which are important for the activation of bioreductive drugs, can be measured spectrophotometrically as the reduction of the artificial electron acceptor cytochrome c. DT-diaphorase activity is determined spectrophotometrically as the dicoumarol-inhibitable, NADH-dependent reduction of cytochrome c in the presence of menadione (Robertson et al., 1994) . The basis of the DT-diaphorase assay is depicted in Figure 1 . DTdiaphorase does not reduce cytochrome c directly. Menadione is a substrate of DT-diaphorase, which reduces it to the hydroquinone, and this product subsequently reduces cytochrome c non-enzymatically. The reduction of menadione is the rate-limiting step in this reaction. Hence, by measuring the rate of reduction of cytochrome c, a measure of DT-diaphorase activity is obtained. However, other enzymes, including cytochrome b5 reductase, are able to reduce cytochrome c directly. Thus, using this method, the total reduction of cytochrome c measured spectrophotometrically comprises both the indirect reduction by DT-diaphorase and the direct reduction by cytochrome b5 reductase (and possibly by other reductase enzymes). The contribution of DT-diaphorase to the overall reduction of cytochrome c is quantified by adding dicoumarol, an inhibitor of this enzyme. To date, it has been assumed that either the non-dicoumarol-inhibitable reduction of cytochrome c (i.e. the residual activity observed in the presence of dicoumarol) (Segura-Aguilar et al., 1990) or the NADH-dependent reduction of cytochrome c (i.e. in the absence of menadione) (Plumb et al., 1994) are equivalent to cytochrome b5 reductase activity. However, neither of these HM Barham et al S 1189 Figure 2 and discussed in the Results section. methods appears to have been validated. In particular, the possible existence of other reductases, which may contribute to the overall reduction of cytochrome c, has not been addressed. In the present study we have investigated whether the two methods assumed to be measures of cytochrome b5 reductase activity are equivalent and valid measurements. In addition, we have used p-hydroxymercuribenzoate (pHMB), a selective inhibitor of cytochrome b5 reductase (Lostanlen et al., 1987) , to quantify the contribution of this enzyme to the total NADHdependent reduction of cytochrome c. The activity of cytochrome b5 reductase in a panel of 22 human tumour cell lines has then been measured using the assay described here, with a view to defining the role of this enzyme in the activation and toxicity of RB90740 and other bioreductive drugs.
Materials and methods
Tissue culture media were obtained from ICRF (Clair Hall Laboratories, UK). Fetal calf serum (FCS), NADH (,B-NADH, disodium salt), cytochrome c (from horse heart) pHMB (p-hydroxymercuribenzoic acid, sodium salt) dicoumarol (3,3'-methylene-bis(4-hydroxy-coumarin) and menadione were purchased from Sigma Chemical Co. (Poole, UK). All other reagents were of analytical grade and were purchased from BDH Ltd (Poole, UK).
Microsomes
Livers were obtained from female C3H mice and stored in liquid nitrogen until use. Microsomes were prepared by differential centrifugation using the method described by Barham (1993) . Microsomal pellets were resuspended in 0.25 M potassium phosphate buffer (pH 7.25) containing 30% glycerol (v/v) and stored as aliquots in liquid nitrogen. Microsomal protein concentration was measured by the Pierce BCA assay (Smith et al., 1985) using bovine serum albumin (BSA) as the standard.
Cells and culture SK-MES, LDAN, CALU-3 and H69 cell lines were gifts from Dr Jane Plumb (CRC Beatson Laboratories, Glasgow, UK). All other cell lines were from MRC stocks (Houlbrook Preparation of cell lysates Lysates were prepared from the pooled contents of two 25 cm2 flasks. Cells in exponential growth phase were washed once with phosphate-buffered saline (PBS) and harvested by the addition of 5 ml trypsin to each flask. The contents of the two flasks were then pooled and centrifuged at 800 r.p.m. for 8 min. The cell pellet was washed in ice-cold PBS (pH 7.1) and then resuspended in 2 ml Nuclear buffer A (10 mM HEPES/potassium hydroxide, pH 7.4, 1.5 mM magnesium chloride, 10 mm potassium chloride, 0.05 mM DTT) and allowed to stand at 4°C for 10 min. Haemocytometer counts of cell numbers were performed during this interval. The suspensions were then sonicated using an MSE Soniprep 150 for 3 x 5 s at a nominal frequency of 23 kHz and an oscillation amplitude of between 5 and 10 Mm. Samples were placed on ice between each sonication. The suspensions were then allowed to stand on ice for a further 10 min, and then centrifuged at 12 000 r.p.m. (7800 g) for 15 min at 4°C. The resulting lysate was removed and stored in liquid nitrogen until required. The protein concentration of the lysates was determined using the Pierce protein assay (Smith et al., 1985) using BSA as the standard.
Cytochrome b5 reductase assay The cytochrome b5 reductase activity of the tumour cell lysates was determined spectrophotometrically as the pHMB-inhibitable, NADH-dependent reduction of cytochrome c. Development of the assay, and rationale for this method are described in the Results section. The final assay protocol is described here.
Lysates were thawed rapidly at 37°C immediately before use and maintained on ice. An assay mixture comprising 900 ,UM NADH and 70 gM cytochrome c in assay buffer (0.05 M phosphate buffer, pH 6.8, prepared by mixing 0.05 M solutions of potassium hydrogen phosphate and potassium dihydrogen phosphate to achieve pH 6.8) was prepared immediately before use by adding 2 ml of a 10 mm stock solution of NADH and 2.8 ml of a 1 mM stock solution of cytochrome c to 35.2 ml of assay buffer. The mixture was wrapped in aluminium foil to prevent light degradation and kept at 37°C. The pHMB was prepared as an 8 mM stock solution in assay buffer containing 20 p1 sodium hydroxide (2 M) per ml buffer. The addition of 25 p1 of this solution to the 1 ml incubation volume achieved a final concentration of 0.2 mM pHMB.
To measure the cytochrome b5 reductase activity of each lysate, paired samples were prepared which contained 1 ml of the assay mixture, 25 Ml of either pHMB or assay buffer and 20 p1 of lysate. The change of absorbance at 550 nm was followed for 1 min. If the rate of change of absorbance was outside the range 0.05 to 0.15 dA min-', the incubation was repeated, modifying the volume of lysate added to the incubation accordingly. In each case it was ensured that the rate of change of absorbance was proportional to the amount of protein added. Initial rates of reaction were calculated based on an extinction coefficient of 2 1 mm-' cm-1 (Williams and Kamin, 1962) Ernster et al. (1962) found the phosphate concentration to be optimal at 0.05 M. Figure 2 shows that the NADH-dependent reduction of cytochrome c was slower at low and high phosphate concentrations, and was optimal at 0.05 M phosphate, at all pHs tested. The activity of cytochrome b5 reductase has been reported to be dependent on pH. Thus, the ability of purified cytochrome b5 reductase to reduce mitomycin C is greater at pH 6.6 than at pH 7.6 (Hodnick and Sartorelli, 1993) . Similarly, cytochrome b5 reductase was found to reduce doxorubicin at pH 6.6, but was unable to catalyse this reduction at pH 7.6 (Hodnick and Sartorelli, 1994) . From Figure 2 it can be seen that the pH dependence of the reduction of cytochrome c by cytochrome b5 reductase was fairly broad and was optimal at pH 6.8. This is in agreement with Guray and Arinc (1991) who showed that the activity of the enzyme purified from sheep lung, measured as the reduction of ferricyanide or partially purified cytochrome b5 as the electron acceptor, was optimal at pH 6.8.
The rate of NADH-dependent reduction of cytochrome c was found to be proportional to cytochrome c concentration in the range of 3 -8 gM (data not shown). Thus, the concentration of 70 /uM used in the assay routinely (taken from the DT-diaphorase assay) was considerably in excess. We confirmed that this substrate concentration was not rate limiting, and nor did it have an inhibitory effect on the enzyme activity. Similarly, the 900 iuM NADH concentration from the DT-diaphorase assay was also shown to be neither rate limiting nor inhibitory.
The NADPH:P450 reductase assay, measured spectrophotometrically as the NADPH-dependent reduction of cytochrome c, requires the presence of KCN (10 (Phillips and Langdon, 1962 Figure 3 . Considering DT-diaphorase activity first (Figure 3a) , it can be seen that in each of the cell lines the dicoumarolinhibitable and menadione-dependent activities are virtually identical. However, the pHMB non-inhibitable activity consistently underestimated the DT-diaphorase activity. This phenomenon appears to be more marked in the cell lines with the higher DT-diaphorase activity. The most likely explanation for this apparent underestimation of DT-diaphorase activity is that pHMB also inhibits DT-diaphorase. This is confirmed by the fact that a 200 gM concentration of pHMB inhibits purified human DT-diaphorase by approximately 35% (data not shown). However, this apparent lack of selectivity of pHMB is not a problem in the cytochrome b5 reductase assay described here because the assay does not incorporate menadione, so that DT-diaphorase makes no contribution to the overall rate of cytochrome c reduction. However, it does mean that different assays are needed for determining the activities of the two enzymes, and that these values cannot be derived simultaneously from a single assay. With respect to the measurement of cytochrome b5 reductase activity, Figure 3b shows the results of the three methods in the three cell lines. In the T47D cell line, which has low DT-diaphorase activity, the three methods give equivalent measures of cytochrome b5 reductase activity. However, in the two high DT-diaphorase activity cell lines, the dicoumarol non-inhibitable activity is a considerable underestimation of cytochrome b5 reductase activity when compared with the other two methods. In each case, the menadione-independent activity, i.e. the NADH-dependent reduction of cytochrome c, is higher than the pHMBinhibitable activity. This indicates that the former overestimates cytochrome b5 reductase activity, possibly owing to the presence of other reductase enzymes that can also reduce cytochrome c directly. The maximum inhibitory concentration of pHMB was 0.2 mM in all three cell lines. Increasing the concentration of pHMB above this did not inhibit cytochrome c reduction any further. However, the proportion of cytochrome c reduction that was inhibited varied between the cell lines. For example, 90% of the cytochrome c reduction could be inhibited in the T47D cell line, whereas only 60% of activity could be inhibited in the ZR75 cell line. Thus, the contribution of enzymes other than cytochrome b5 reductase to the overall reduction of cytochrome c varies between the lines. For this reason, pHMB-inhibitable activity was considered to be the more accurate measure of cytochrome b5 reductase activity.
Assay reproducibility
The inter-and intra-assay variation was Table I , and the relative proportions of the pHMB-inhibitable and non-inhibitable activities shown in Figure 4 . The values for non-inhibitable activity ranged from approximately 4 (MDA-231, T47D) to 60 (ZR75) nmol cytochrome c reduced min-' mg-' protein and represented up to about 40% of the total reduction of cytochrome c. In some cases cytochrome b5 reductase activity accounted for nearly all of the NADH-dependent reduction of cytochrome c, leaving a residual activity that was close to the limit of detection of the assay.
Discussion
The 'enzyme-directed' approach to bioreductive drug development (Workman and Walton, 1989; Workman and Stratford, 1993 ) is based on variation in the ability of different tumour types to respond to bioreductive compounds combined with knowledge of the levels of various reductase enzymes in these cell lines/tumours. It involves both the rational design of compounds as targets for activation by specific enzymes and enzyme profiling of both tumour tissue and surrounding healthy tissue in order to define likely targets for drug activation. For example, the levels of DTdiaphorase have been shown to vary 10 000-fold in a panel of 23 tumour cell lines (Robertson et al., 1994 ) and also to be elevated in tumour tissue compared with surrounding noncancerous tissue (Riley and Workman, 1992) . The aerobic toxicity of the indoloquinone E09 correlates highly with intracellular DT-diaphorase activity (Plumb et al., 1994; Robertson et al., 1994) . Therefore, E09 should be targeted at tumours with high levels of DT-diaphorase, and would be expected to be of litle or no therapeutic benefit when used as a single agent to treat tumours with low DT-diaphorase levels. Knowledge of the substrate structure requirements of DT-diaphorase should enable the rational design of analogues of E09 for targeting at DT-diaphorase-rich tumours. Another example of the 'enzyme-directed' approach is activation of the di-N-oxide bioreductive drug, tirapazamine (SR 4233), in a panel of human breast cancer cell lines (Patterson et al., 1995) . Under hypoxic conditions both the cytotoxicity of the drug and its conversion to a deoxygenated product correlate with NADPH: cytochrome P450 reductase activity.
The metabolic activation of the aromatic mono-N-oxide bioreductive drug, RB90740, has been shown to be mediated, at least in part, by cytochrome b5 reductase (Barham and Stratford, 1996) . However, in order to investigate the overall importance of this enzyme in determining the cytotoxicity of RB90740, it was necessary to develop an assay for quantifying the level of enzyme in cell lines and tumours. Methods reported in the literature do not appear to have been validated, i.e. the non-dicoumarol-inhibitable reduction of cytochrome c (Segura-Aguilar et al., 1990) or the NADHdependent reduction of cytochrome c (Plumb et al., 1994) , and assume that cytochrome b5 reductase is the only enzyme responsible for the NADH-dependent reduction of cytochrome c. Our data indicate that this assumption is not valid. From Figure 4 it is evident that cytochrome b5 reductase activity does not account for all of the NADH-dependent reduction of cytochrome c in any cell line, as assessed using pHMB as a selective inhibitor. Moreover, in some cell lines, for example ZR75, the cytochrome b5 reductase activity accounts for only 60% of the total reduction of cytochrome c. This, therefore, suggests that the method of Plumb et al. (1994) consistently overestimates cytochrome b5 reductase activity, possibly by as much as 100%.
The method of Segura-Aguilar et al. (1990) also assumes that dicoumarol is a selective inhibitor of DT-diaphorase. We found that dicoumarol did not inhibit the NADH-dependent reduction of cytochrome c catalysed by mouse liver microsomes (data not shown). However, Hodnick and Sartorelli (1993) have shown that dicoumarol inhibits the reduction of mitomycin C by purified cytochrome b5 reductase by 24% and 57% at concentrations of 100 lM and 300 iM respectively. The concentration of dicoumarol used in the DT-diaphorase assay is 100 gM. Our data support this latter finding. From Figure 3b it can be seen that the dicoumarol non-inhibitable reduction of cytochrome c is an underestimation of cytochrome b5 reductase activity, suggesting that dicoumarol is inhibiting cytochrome b5 reductase to some extent.
Thus, our data show that the method used by SeguraAguilar et al. (1990) here. However, the assay they used was essentially the DTdiaphorase assay, omitting menadione. Their assay incorporated BSA, which stimulates DT-diaphorase activity (Ernster et al., 1962) and used Tris buffer rather than phosphate buffer. We have found cytochrome b5 reductase activity is similar in the two types of buffer and does not appear to be stimulated by BSA (0.14%), at least in phosphate buffer (data not shown). However, the enzyme activities measured by Plumb et al. (1994) were the NADH-dependent reduction of cytochrome c. We have shown here that this method overestimates cytochrome b5 reductase activity, in some cases by as much as 90-100%, depending on the presence of other reductase enzymes. On this basis we feel that our method is more fully validated, and gives a more accurate reflection of intracellular cytochrome b5 reductase activities.
Spectrophotometric assays are used widely to measure the activity of reductase enzymes. Ideally, the assay for cytochrome b5 reductase described here should be validated more fully using an immunological method. For example, selective antibodies to cytochrome b5 reductase could be used to inhibit the enzyme, and this level of inhibition compared with that achieved by pHMB. However, such antibodies are not currently available. Also. it must be considered that antibodies are not always entirely selective. and. therefore. may not give an accurate measure. An alternative approach might be to compare the levels of cytochrome b5 reductase protein. measured using Western blotting, uWith the reductase activity measured using the cytochrome c assay. Unfortunately. this method also requires antibodies to the enzyme. and also assumes that all the protein is active. In the absence of appropriate antibodies. the assay that we have described here. measuring cytochrome b. reductase activity as the pHMB-inhibitable reduction of cytochrome c. is suitable for comparing levels of cytochrome b5 reductase in different tumour cell lines. and is certainly more accurate than either the dicoumarol non-inhibitable (Segura-Aguilar et al.. 1990) or the NADH-dependent (Plumb et al.. 1994 ) reduction of cytochrome c.
We have used the assay described here to measure a 7-fold range in activity of cytochrome b5 reductase in a panel of 22 human tumour cell lines. This variation is far less than has been demonstrated for the reductase DT-diaphorase. However, Patterson et al. (1995) 
